The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Greten S, Wegner F, Jensen I, Krey L, Rogozinski S, Fehring M, Heine J, Doll-Lee J, Pötter-Nerger M, Zeitzschel M, Hagena K, Pedrosa DJ, Eggers C, Bürk K, Trenkwalder C, Claus I, Warnecke T, Süß P, Winkler J, Gruber D, Gandor F, Berg D, Paschen S, Classen J, Pinkhardt EH, Kassubek J, Jost WH, Tönges L, Kühn AA, Schwarz J, Peters O, Dashti E, Priller J, Spruth EJ, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J, Höglinger GU, Klietz M (2023)

Publication Type: Journal article

Publication year: 2023

Journal

DOI: 10.1007/s00415-023-12006-4

Abstract

Background: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. Objectives: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Methods: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®. Results: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions. Conclusions: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

Authors with CRIS profile

Additional Organisation(s)

Involved external institutions

Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Münster Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Klinikum Osnabrück Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE) Knappschaftskrankenhaus Bottrop Germany (DE) Kliniken Schmieder Germany (DE) Paracelsus-Elena-Klinik Kassel Germany (DE) Christian-Albrechts-Universität zu Kiel Germany (DE) Parkinson-Klinik Ortenau Germany (DE) Universität Ulm Germany (DE) Universität Leipzig Germany (DE) INNKLINIKUM HAAG Germany (DE) Ruhr-Universität Bochum (RUB) Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE)

How to cite

APA:

Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M.,... Klietz, M. (2023). The comorbidity and co-medication profile of patients with progressive supranuclear palsy. Journal of Neurology. https://dx.doi.org/10.1007/s00415-023-12006-4

MLA:

Greten, Stephan, et al. "The comorbidity and co-medication profile of patients with progressive supranuclear palsy." Journal of Neurology (2023).

BibTeX: Download